Publications by authors named "Hideki Garren"

Claim this Profile
M
Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.
Shannon Kolind, Shawna Abel, Carolyn Taylor, Roger Tam, Cornelia Laule, Hideki Garren

Neuroimage Clin· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Anthony Traboulsee, Benjamin M Greenberg, Jeffrey L Bennett, Lech Szczechowski, Edward Fox, Hideki Garren

Lancet Neurol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a.
Erin L MacMillan, Julia J Schubert, Irene M Vavasour, Roger Tam, Alexander Rauscher, Hideki Garren

Mult Scler J Exp Transl Clin· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis.
Jonathan O'Muircheartaigh, Irene Vavasour, Emil Ljungberg, David K B Li, Alexander Rauscher, Hideki Garren

Hum Brain Mapp· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Benjamin Turner, Bruce A C Cree, Ludwig Kappos, Xavier Montalban, Caroline Papeix, Hideki Garren

J Neurol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced imaging findings in progressive solitary sclerosis: a single lesion or a global disease?
Lisa Eunyoung Lee, Jillian K Chan, Emilie Nevill, Adam Soares, Irene M Vavasour, Hideki Garren

Mult Scler J Exp Transl Clin· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
Jerry S Wolinsky, Xavier Montalban, Stephen L Hauser, Gavin Giovannoni, Patrick Vermersch, Hideki Garren

Ann Neurol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.
Eva Havrdová, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Hans-Peter Hartung, Hideki Garren

Mult Scler J Exp Transl Clin· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Hideki Garren

N Engl J Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Hideki Garren

N Engl J Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
Eva Havrdová, Anna Belova, Alla Goloborodko, Anne Tisserant, Andrew Wright, Hideki Garren

J Neurol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.
Ghanashyam Sarikonda, Sowbarnika Sachithanantham, Yulia Manenkova, Tinalyn Kupfer, Amanda Posgai, Hideki Garren

PLoS One· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes.
Bart O Roep, Nanette Solvason, Peter A Gottlieb, Joana R F Abreu, Leonard C Harrison, Hideki Garren

Sci Transl Med· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of MS lesions to black holes under DNA vaccine treatment.
Athina Papadopoulou, Stefanie von Felten, Stefan Traud, Amena Rahman, Joanne Quan, Hideki Garren

J Neurol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference. October 20-22, 2010, San Francisco, CA, USA.
Hideki Garren

IDrugs· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple sclerosis therapies: molecular mechanisms and future.
Paulo Fontoura, Hideki Garren

Results Probl Cell Differ· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene Based Vaccines: Optimising Development and Delivery - A marcus evans Conference.
Hideki Garren

IDrugs· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA vaccines for autoimmune diseases.
Hideki Garren

Expert Rev Vaccines· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites.
Nanette Solvason, Ya-Ping Lou, Wendy Peters, Erica Evans, Josefina Martinez, Hideki Garren

J Immunol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A DNA vaccine for multiple sclerosis.
Hideki Garren

Expert Opin Biol Ther· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.
Hideki Garren, William H Robinson, Eva Krasulová, Eva Havrdová, Congor Nadj

Ann Neurol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Amit Bar-Or, Timothy Vollmer, Jack Antel, Douglas L Arnold, Caroline Anita Bodner, Hideki Garren

Arch Neurol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
Paulo Fontoura, Hideki Garren, Lawrence Steinman

Int Rev Immunol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease.
Peggy P Ho, Paulo Fontoura, Michael Platten, Raymond A Sobel, Jason J DeVoss, Hideki Garren

J Immunol· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite.
Michael Platten, Peggy P Ho, Sawsan Youssef, Paulo Fontoura, Hideki Garren

Science· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis